AllerGenis

Executive Summary

AllerGenis is a US-based diagnostics company developing advanced, personalized food allergy tests using a proprietary platform that integrates machine learning and immunology. Founded in 2015 and headquartered in Philadelphia, the company aims to improve diagnostic accuracy beyond traditional skin prick and IgE blood tests by analyzing patient-specific immune responses. Its technology targets a significant unmet need in food allergy management, where misdiagnosis and ambiguity are common. AllerGenis is privately held and has not disclosed funding or valuation; however, its innovative approach positions it to capture value in the growing food allergy diagnostics market, projected to reach $1.5 billion by 2028. The company's clinical validation and regulatory pathway will be critical to its success. With no commercial products yet, AllerGenis must navigate FDA clearance and demonstrate clinical utility. The company's low public profile suggests early-stage development, but its technology could be disruptive if successfully validated. Conviction is moderate given the early stage and lack of publicly available traction.

Upcoming Catalysts (preview)

• Q3 2026Publication of clinical validation study results70% success
• TBDStrategic partnership or licensing deal with a larger diagnostics company50% success
• Q3 2026Series A or seed funding round announcement40% success